尿路感染症検査市場：適応症別、検査キット別、検査項目別、エンドユーザー別-2025-2030年の世界予測

尿路感染症検査市場は、2023年に14億米ドルと評価され、2024年には14億7,000万米ドルに達すると予測され、CAGR 4.75％で成長し、2030年には19億4,000万米ドルに達すると予測されています。

尿路感染症（UTI）検査市場には、膀胱、腎臓、尿管、尿道を含む泌尿器系の感染症を特定するために使用される様々な診断ツールや処置が含まれます。尿路結石検査の必要性は、特に女性、高齢者、糖尿病や脊髄損傷などの特定の危険因子を持つ人々の間で、この疾患が蔓延していることが背景にあります。アプリケーションには、ポイントオブケア検査、家庭用検査キット、および細菌同定と抗生物質感受性試験に重点を置いたラボベースの診断が含まれます。主なエンドユーザーには、病院、診断研究所、研究機関、在宅ヘルスケア環境などがあります。市場成長は、尿路結石症の増加、迅速検査技術の進歩、非侵襲的で正確な診断方法に対する需要の高まりなどの要因に影響されています。最新の市場開拓としては、AIベースの診断ツールの開発、家庭用検査キットへのIoTの統合、アンメット・メディカル・ニーズの高い新興国市場での展開などが挙げられます。企業はこれらの機会を活用するため、技術強化や地域拡大のための共同研究や提携に注力すべきです。しかし、高度な診断システムに伴う高コストや、治療プロトコルに影響を及ぼす偽陰性や偽陽性の可能性などの制約が、市場成長の課題となっています。規制上のハードルや臨床的検証の必要性も大きな課題となっています。事業成長のための技術革新分野としては、費用対効果の高い携帯型診断装置の開発、微生物培養技術の強化、病原体の遺伝子同定の拡大などが挙げられます。市場は競合が激しく細分化されているが、個別化医療や遠隔診断のための遠隔医療の統合には大きな可能性があります。迅速なバイオマーカー同定と耐性パターン追跡の継続的研究が極めて重要になります。企業は、研究開発への投資と戦略的パートナーシップを優先させ、この複雑な市場環境を乗り切り、ヘルスケアプロバイダーと患者の進化するニーズを満たすイノベーションを促進すべきです。

市場力学：急速に進化する尿路感染症検査市場の主要市場インサイトを公開

尿路感染症検査市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の尿路感染症の増加
  • 抗生物質の過剰使用と薬剤耐性の増加による複雑な尿路感染症
• 市場抑制要因
  • 尿路感染症検査ソリューションの製品回収問題
• 市場機会
  • 新しい画像技術や検査機器の開発の高まり
  • 迅速診断の普及に向けた政府の積極的な取り組み
• 市場の課題
  • 尿路感染症に関する社会的スティグマ

ポーターのファイブフォース：尿路感染症検査市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：尿路感染症検査市場における外部からの影響の把握

外部マクロ環境要因は、尿路感染症検査市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析尿路感染症検査市場における競合情勢の把握

尿路感染症検査市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス尿路感染症検査市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、尿路感染症検査市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨尿路感染症検査市場における成功への道筋を描く

尿路感染症検査市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で尿路感染症の発生率が増加
    • 抗生物質の過剰使用と薬剤耐性の増加による複雑な尿路感染症
  • 抑制要因
    • 尿路感染症検査ソリューションによる製品リコール問題
  • 機会
    • 新しい画像技術と検査装置の開発の増加
    • 迅速診断を増やすための政府の好ましい取り組み
  • 課題
    • 尿路感染症に関する社会的偏見
• 市場セグメンテーション分析
  • 検査：抗生物質の処方を避けるため感受性検査の利用が増加
  • エンドユーザー：細菌の存在を検出する診断ラボにおける尿路感染症検査の潜在能力が高い
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 尿路感染症検査市場適応症別

• 膀胱炎
• 腎盂腎炎
• 尿道炎
• 膣炎

第7章 尿路感染症検査市場テストキット

• 家庭用検査キット
• 臨床検査キット

第8章 尿路感染症検査市場テスト別

• 感受性試験
• 尿検査
• 尿培養

第9章 尿路感染症検査市場：エンドユーザー別

• 診断検査室
• 病院
• 腎症クリニック

第10章 南北アメリカの尿路感染症検査市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の尿路感染症検査市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの尿路感染症検査市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • PathogenDxの尿路感染症検査向け環境効率の高いD3アレイプラットフォームアプローチ
  • Vivoo、UTI診断を進化させるスマート在宅検査ソリューションを発表
  • テキサス大学ダラス校の研究者が開発した新しい診断センサー
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Accelerate Diagnostics, Inc.
• ACON Laboratories, Inc.
• Beckman Coulter, Inc. by Danaher Corporation
• Bio-Rad Laboratories, Inc.
• bioMerieux SA
• Cardinal Health Inc.
• Chungdo Pharm Co., Ltd.
• F. Hoffmann-La Roche Ltd.
• Genetworx, LLC
• Module Innovations Pvt. Ltd.
• Piramal Pharma Limited
• QIAGEN GmbH
• Randox Laboratories Ltd.
• Siemens Healthineers
• Stryker Corporation
• SYSMEX CORPORATION
• T2 Biosystems, Inc.
• Thermo Fisher Scientific Inc.
• Vivosens Inc.

LIST OF FIGURES

• FIGURE 1. URINARY TRACT INFECTION TESTING MARKET RESEARCH PROCESS
• FIGURE 2. URINARY TRACT INFECTION TESTING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. URINARY TRACT INFECTION TESTING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. URINARY TRACT INFECTION TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. URINARY TRACT INFECTION TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. URINARY TRACT INFECTION TESTING MARKET DYNAMICS
• TABLE 7. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CYSTITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY PYELONEPHRITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY URETHRITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY VAGINITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY HOME TEST KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY LABORATORY TEST KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY SUSCEPTIBILITY TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY URINALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY URINE CULTURES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY NEPHROPATHY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 36. CANADA URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 37. CANADA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 38. CANADA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 39. CANADA URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 58. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 59. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 60. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 61. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 62. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 64. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 65. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 131. ITALY URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 132. ITALY URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 133. ITALY URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 134. ITALY URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 147. POLAND URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 148. POLAND URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 149. POLAND URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 150. POLAND URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 151. QATAR URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 152. QATAR URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 153. QATAR URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 154. QATAR URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM URINARY TRACT INFECTION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST KITS, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM URINARY TRACT INFECTION TESTING MARKET SIZE, BY TESTS, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 191. URINARY TRACT INFECTION TESTING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 192. URINARY TRACT INFECTION TESTING MARKET, FPNV POSITIONING MATRIX, 2023

The Urinary Tract Infection Testing Market was valued at USD 1.40 billion in 2023, expected to reach USD 1.47 billion in 2024, and is projected to grow at a CAGR of 4.75%, to USD 1.94 billion by 2030.

The urinary tract infection (UTI) testing market encompasses various diagnostic tools and procedures used to identify infections in the urinary system, including the bladder, kidneys, ureters, and urethra. The necessity for UTI testing is driven by the prevalence of the condition, particularly among women, the elderly, and those with certain risk factors such as diabetes or spinal cord injuries. Applications include point-of-care testing, home testing kits, and laboratory-based diagnostics, with a focus on bacteria identification and antibiotic susceptibility testing. Key end-users include hospitals, diagnostic laboratories, research institutes, and home healthcare settings. Market growth is influenced by factors such as increasing UTI incidences, advancements in rapid testing technologies, and a growing demand for non-invasive and accurate diagnostic methods. Latest opportunities include the development of AI-based diagnostic tools, integration of IoT in home testing kits, and expansion in emerging markets with high unmet medical needs. Companies should focus on collaborations and partnerships for technology enhancement and geographic expansion to leverage these opportunities. However, market growth is challenged by limitations such as high costs associated with advanced diagnostic systems and the potential for false-negative or false-positive outcomes, which can affect treatment protocols. Regulatory hurdles and the need for clinical validation also pose significant challenges. For business growth, areas of innovation include developing cost-effective and portable diagnostic devices, enhancing microbial culture techniques, and expanding the genetic identification of pathogens. The market is competitive and fragmented, with significant potential in personalized medicine and the integration of telemedicine for remote diagnosis. Continued research into rapid biomarker identification and resistance pattern tracking will be pivotal. Businesses should prioritize investment in R&D and strategic partnerships to navigate this complex market landscape, fostering innovations that meet the evolving needs of healthcare providers and patients alike.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Urinary Tract Infection Testing Market

The Urinary Tract Infection Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing incidence of urinary tract infections worldwide
  • Complicated UTIs due to a rise in excessive use of antibiotics and drug resistance
• Market Restraints
  • Product recall issues with the urinary tract infection testing solutions
• Market Opportunities
  • Rising development of new imaging technologies and testing devices
  • Favorable initiatives by the government to increase rapid diagnostics
• Market Challenges
  • Social stigma concerning urinary tract infections

Porter's Five Forces: A Strategic Tool for Navigating the Urinary Tract Infection Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Urinary Tract Infection Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Urinary Tract Infection Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Urinary Tract Infection Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Urinary Tract Infection Testing Market

A detailed market share analysis in the Urinary Tract Infection Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Urinary Tract Infection Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Urinary Tract Infection Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Urinary Tract Infection Testing Market

A strategic analysis of the Urinary Tract Infection Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Urinary Tract Infection Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Accelerate Diagnostics, Inc., ACON Laboratories, Inc., Beckman Coulter, Inc. by Danaher Corporation, Bio-Rad Laboratories, Inc., bioMerieux SA, Cardinal Health Inc., Chungdo Pharm Co., Ltd., F. Hoffmann-La Roche Ltd., Genetworx, LLC, Module Innovations Pvt. Ltd., Piramal Pharma Limited, QIAGEN GmbH, Randox Laboratories Ltd., Siemens Healthineers, Stryker Corporation, SYSMEX CORPORATION, T2 Biosystems, Inc., Thermo Fisher Scientific Inc., and Vivosens Inc..

Market Segmentation & Coverage

This research report categorizes the Urinary Tract Infection Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Indication, market is studied across Cystitis, Pyelonephritis, Urethritis, and Vaginitis.
• Based on Test Kits, market is studied across Home Test Kits and Laboratory Test Kits.
• Based on Tests, market is studied across Susceptibility Testing, Urinalysis, and Urine Cultures.
• Based on End User, market is studied across Diagnostic Laboratories, Hospitals, and Nephropathy Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing incidence of urinary tract infections worldwide
    • 5.1.1.2. Complicated UTIs due to a rise in excessive use of antibiotics and drug resistance
  • 5.1.2. Restraints
    • 5.1.2.1. Product recall issues with the urinary tract infection testing solutions
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising development of new imaging technologies and testing devices
    • 5.1.3.2. Favorable initiatives by the government to increase rapid diagnostics
  • 5.1.4. Challenges
    • 5.1.4.1. Social stigma concerning urinary tract infections
• 5.2. Market Segmentation Analysis
  • 5.2.1. Tests: Rising usage of susceptibility testing to avoid prescribing antibiotics
  • 5.2.2. End User: High potential for urinary tract infection testing in diagnostic laboratories to detect the presence of bacteria
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Urinary Tract Infection Testing Market, by Indication

• 6.1. Introduction
• 6.2. Cystitis
• 6.3. Pyelonephritis
• 6.4. Urethritis
• 6.5. Vaginitis

7. Urinary Tract Infection Testing Market, by Test Kits

• 7.1. Introduction
• 7.2. Home Test Kits
• 7.3. Laboratory Test Kits

8. Urinary Tract Infection Testing Market, by Tests

• 8.1. Introduction
• 8.2. Susceptibility Testing
• 8.3. Urinalysis
• 8.4. Urine Cultures

9. Urinary Tract Infection Testing Market, by End User

• 9.1. Introduction
• 9.2. Diagnostic Laboratories
• 9.3. Hospitals
• 9.4. Nephropathy Clinics

10. Americas Urinary Tract Infection Testing Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Urinary Tract Infection Testing Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Urinary Tract Infection Testing Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. PathogenDx's Eco-efficient D3 Array Platform Approach for Urinary Tract Infection Testing
  • 13.3.2. Vivoo Unveils Smart At-Home Testing Solution Advancing UTI Diagnostics
  • 13.3.3. A Novel Diagnostic Sensor Developed by University of Texas at Dallas Researchers
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Accelerate Diagnostics, Inc.
• 3. ACON Laboratories, Inc.
• 4. Beckman Coulter, Inc. by Danaher Corporation
• 5. Bio-Rad Laboratories, Inc.
• 6. bioMerieux SA
• 7. Cardinal Health Inc.
• 8. Chungdo Pharm Co., Ltd.
• 9. F. Hoffmann-La Roche Ltd.
• 10. Genetworx, LLC
• 11. Module Innovations Pvt. Ltd.
• 12. Piramal Pharma Limited
• 13. QIAGEN GmbH
• 14. Randox Laboratories Ltd.
• 15. Siemens Healthineers
• 16. Stryker Corporation
• 17. SYSMEX CORPORATION
• 18. T2 Biosystems, Inc.
• 19. Thermo Fisher Scientific Inc.
• 20. Vivosens Inc.